Photo from wikipedia
Key Points Question What is the effect of P2Y12 inhibition, a proposed therapeutic target and preventive strategy, on clinical outcomes in critically ill patients hospitalized for COVID-19? Findings In this… Click to show full abstract
Key Points Question What is the effect of P2Y12 inhibition, a proposed therapeutic target and preventive strategy, on clinical outcomes in critically ill patients hospitalized for COVID-19? Findings In this randomized clinical trial that included 949 participants, use of a P2Y12 inhibitor did not result in a greater number of days alive and free of cardiovascular or respiratory organ support up to day 21 of the index hospitalization. Meaning These data do not support routine use of a P2Y12 inhibitor in critically ill patients hospitalized for COVID-19.
Journal Title: JAMA Network Open
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!